Pyxis Oncology (PYXS) Gains from Investment Securities (2021 - 2025)
Pyxis Oncology (PYXS) reported Gains from Investment Securities of $900000.0 for Q4 2025, up 1600.0% year-over-year from $52941.2 in Q4 2024, and down 92.85% quarter-over-quarter from $12.6 million in Q3 2025.
Pyxis Oncology (PYXS) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 5 years of Gains from Investment Securities data on file, last reported at $900000.0 in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $900000.0, up 1600.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $787900.0 (up 6611.57% YoY), and the FY2025 annual result was $12.5 million, up 28.39% from the prior year.
- Gains from Investment Securities slipped to $900000.0 in Q4 2025 per PYXS's latest filing, from $12.6 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $14.3 million in Q4 2022 and troughed at -$60000.0 in Q4 2024.
- A 5-year average of $3.8 million and a median of $900000.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities slumped 100.36% in 2023, then jumped 1283312.0% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $5.9 million in 2021, then soared by 141.22% to $14.3 million in 2022, then tumbled by 100.36% to -$52100.0 in 2023, then retreated by 15.16% to -$60000.0 in 2024, then soared by 1600.0% to $900000.0 in 2025.
- Business Quant data shows PYXS's Gains from Investment Securities at $900000.0 in Q4 2025, $12.6 million in Q3 2025, and $697237.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 12.58 Mn |
| Sep 30, 2025 | 12.58 Mn |
| Jun 30, 2025 | 697,237.00 |
| Jun 30, 2025 | 697,237.00 |
| Mar 31, 2025 | 12.23 Mn |
| Mar 31, 2025 | 12.23 Mn |
| Dec 31, 2024 | -60,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Jun 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 6.89 Mn |
| Mar 31, 2024 | 6.89 Mn |
| Dec 31, 2023 | -52,100.00 |
| Dec 31, 2023 | -52,100.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | 100.00 |
| Jun 30, 2023 | 100.00 |